STANDARD BIOTOOLS INC.

LAB Nasdaq CIK: 0001162194

Company Information

Industry Laboratory Analytical Instruments
SIC Code 3826
Entity Type operating
SEC Category Accelerated filer
State of Incorporation DE
Business Address 50 MILK STREET, BOSTON, MA, 02109
Mailing Address 50 MILK STREET, BOSTON, MA, 02109
Phone 6502666000
Fiscal Year End 1231
EIN 770513190

Financial Overview

FY2025

$-0.20
EPS

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 16, 2026 View on SEC
4 Insider stock transaction report March 2, 2026 View on SEC
4 Insider stock transaction report March 2, 2026 View on SEC
4 Insider stock transaction report March 2, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
8-K Current report of material events February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
8-K/A Current report amendment February 5, 2026 View on SEC
8-K Current report of material events January 30, 2026 View on SEC

Annual Reports

10-K March 16, 2026
  • Strategic merger agreement with Palamedrix, valued at $200 million, to expand into high-growth proteomics and personalized medicine diagnostics.
  • Increased R&D investment to $50 million, demonstrating a strong commitment to innovation and new product development despite financial losses.
View Analysis

Material Events

8-K Strategy Change January 30, 2026
High Impact
  • Received $350 million upfront cash payment, with potential for an additional $75 million in future earnouts.
  • Dramatically improved financial flexibility and balance sheet through significant cash infusion.
View Analysis

Insider Trading

STRONG BUY 1 insiders 8 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 3826)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.